6% [47/63] PS-341 datasheet vs 75.0% [24/32]). Of the 65 patients who initially received 2250 mg/day TVR, 41 were IL28B TT, 21 were IL28B non-TT and three were

undetermined. RVR (83.3% [20/24] vs 80.0% [12/15], P > 0.999) and SVR12 (81.8% [18/22] vs 94.1% [16/16], P = 0.363) rates were similar in IL28B TT patients with low and high IP-10. In contrast, the RVR rate was significantly higher in IL28B non-TT patients with low than high IP-10 (88.9% [8/9] vs 33.3% [4/12], P = 0.024), whereas SVR12 rate in patients with IL28B non-TT and low IP-10 was not significantly higher than that in patients with IL28B non-TT and high IP-10 (66.7% [6/9] vs 33.3% [4/12], P = 0.198). Of the 32 patients who initially received 1500 mg/day TVR, 26 were IL28B TT and six were IL28B non-TT. In terms of RVR and SVR12 rates, the difference between patients with IL28B

TT and low IP-10 and those with IL28B TT and high IP-10 was not significant (RVR, 100% [11/11] vs 71.4% [10/14], P = 0.105; SVR12, 91.7% [11/12] vs 71.4% [10/14], P = 0.330). Because of the small sample size (n = 6), we did not perform subgroup analyses of patients with IL28B non-TT. To our knowledge, few studies have examined the effects of pretreatment serum IP-10 concentration on virological responses in genotype 1 CHC patients treated with TVR-based triple therapy.[27] Baseline IP-10 has been found predictive of treatment outcomes in HCV genotype 1-infected patients treated with PEG IFN and RBV.[17, 18, 25] IL28B SNP has also been associated with virological responses to antiviral treatment in HCV-infected patients.[12, 13] However, MK-1775 supplier currently, data on combining these predictors in patients

with genotype 1 HCV infection treated with TVR-based triple therapy are limited; hence, the reason for the current study. Our multivariate analyses showed that pretreatment serum IP-10 concentration was a significant predictor of O-methylated flavonoid RVR, but not of SVR12. In patients with the IL28B risk allele, the RVR rate was significantly higher in those with low than high IP-10 concentrations. The SVR12 rate also tended to be higher in the former subgroup, although the difference did not reach statistical significance, probably due to the small sample size. Similar results were observed in patients receiving initial TVR doses of 1500 and 2250 mg/day per protocol. These results suggest that, in patients with HCV genotype 1 treated with TVR-based triple therapy, baseline IP-10 level is useful for predicting virological response, especially in those with the IL28B risk allele who are considered difficult to treat. We found that pretreatment serum IP-10 differed significantly (P = 0.001) in patients who did and did not achieve RVR. Low systemic IP-10 was found to predict a favorable first-phase decline in HCV RNA and RVR during treatment with PEG IFN and RBV.